Comparative Study of Different Dosage Regimen of Cisplatin Combined Vinorelbine in the Treatment of Non-small Cell Lung Cancer

OBJECTIVE:To evaluate the therapeutic efficacy and toxic reactions of Cisplatin(DDP)in different dosage regimen in combination of vinorelbine(NVB)in the treatment of non-small cell lung cancer(NSCLC).METHODS:123 NSCLC(Ⅲ～Ⅳ)patients were randomly divided into two groups:67 patients were treated with low dose cisplatin(LD-DDP:20 mg·m-2,d1～5,iv gtt)plus vinorelbine(25 mg·m-2,d1,d8.iv gtt),and another 56 with high dose cisplatin(HD-DDP:60 mg·m-2,d1,d2.iv gtt)plus vinorelbine(25 mg·m-2,d1,d8.iv gtt)for 21 days(1 course of treatment).Curative effects were evaluated after treatment of 2 courses.RESULTS:CR+PR rate of high dose DDP group was 41.1% versus 28.4% of low dose DDD group(P0.05).Incidence rate of leukopenia in the high dose DDP group was significantly higher than in the low dose DDP group(87.5% vs.71.6%)(P0.05).However,there was no significant difference between high dose DDP group and low dose DDP group in leukopenia of Ⅲ～Ⅳ degree(P0.05).CONCLUSION:The therapeutic effects of high dose DDP and LD-DDP group were equivalent.The incidence rate of toxic effect was significantly higher in the HD-DDP group than in the LD-DDP group,but the rate of serious toxic effect in the two groups was similar.